Get the Stockscreener App
41.19
1.01%
-0.25
Atricure Inc stock is traded at $41.19, with a volume of 29,230.
It is down -1.01% in the last 24 hours and up +2.91% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
See More
Previous Close:
$41.44
Open:
$41.5
24h Volume:
29,230
Relative Volume:
0.06
Market Cap:
$2.04B
Revenue:
$499.95M
Net Income/Loss:
$-36.36M
P/E Ratio:
-53.49
EPS:
-0.77
Net Cash Flow:
$24.22M
1W Performance:
+3.69%
1M Performance:
+2.91%
6M Performance:
+30.06%
1Y Performance:
+25.44%
1-Day Range:
$41.02
$41.84
1-Week Range:
$38.68
$41.84
52-Week Range:
$28.29
$43.11
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
41.06 | 2.06B | 499.95M | -36.36M | 24.22M | -0.77 |
|
ISRG
Intuitive Surgical Inc
|
595.44 | 210.16B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
205.88 | 58.51B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
81.15 | 40.19B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
247.08 | 36.37B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
40.48 | 31.30B | 27.43B | 1.27B | 1.01B | 1.5829 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Resumed | JP Morgan | Overweight |
| Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-29-23 | Initiated | UBS | Buy |
| Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Reiterated | Needham | Buy |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-24-20 | Reiterated | Needham | Buy |
| Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Apr-12-19 | Initiated | JP Morgan | Overweight |
| Oct-04-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Stifel | Buy |
| Jun-18-18 | Reiterated | Needham | Buy |
| Apr-27-18 | Reiterated | Needham | Buy |
| Jan-16-18 | Reiterated | Needham | Buy |
| Nov-02-17 | Reiterated | Needham | Buy |
| Jul-28-17 | Reiterated | Needham | Buy |
| May-30-17 | Resumed | Piper Jaffray | Overweight |
| Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
| Oct-28-15 | Reiterated | Needham | Buy |
| Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
AtriCure, Inc. (NASDAQ:ATRC) Nasdaq Index Fund Medical Devices - Kalkine Media
AtriCure Inc (ATRC) Product Pipeline Analysis Report 2025: Portfolio Led by Isolator Synergy, AtriCl - PharmiWeb.com
AtriCure Inc (ATRC) Product Pipeline Analysis Report 2025: Portfolio Led by Isolator Synergy, AtriClip, Hybrid AF Therapy, and cryoICE cryoSPHERE TechnologiesResearchAndMarkets.com - The AI Journal
Liquidity Mapping Around (ATRC) Price Events - Stock Traders Daily
AtriCure (ATRC): Assessing Valuation After First-In-Human PFA/RFA Procedures and Renewed Analyst Optimism - Yahoo Finance
Assessing AtriCure’s Valuation After a 33.4% Rally in 2025 - Yahoo Finance
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year? - sharewise.com
AtriCure (NASDAQ:ATRC) Stock Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
What AtriCure (ATRC)'s First Dual-Energy PFA–RFA Procedures Mean For Shareholders - Sahm
Big Money Moves: Will AtriCure Inc stock benefit from green energy trendsVolume Spike & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Analysts See an Over 26% Upside in AtriCure (ATRC) - Insider Monkey
15 Most Promising Mid-Cap Healthcare Stocks Under $50 - Insider Monkey
AtriCure price target raised to $48 from $42 at JPMorgan - MSN
AtriCure announces first patients treated with dual energy platform - MSN
Quarterly Recap: What valuation multiples suggest for AtriCure Inc stock - moha.gov.vn
Is AtriCure Inc. stock a buy in volatile marketsShare Buyback & Smart Allocation Stock Tips - Улправда
AtriCure (ATRC) Is Up 6.32% in One Week: What You Should Know - Yahoo Finance
Why AtriCure Inc. stock is favored by top institutionsQuarterly Earnings Summary & Safe Investment Capital Preservation Plans - DonanımHaber
Will AtriCure Inc. stock benefit from green energy trends2025 Growth vs Value & AI Powered Market Entry Ideas - DonanımHaber
Canaccord Genuity Reaffirms Their Buy Rating on Atricure (ATRC) - The Globe and Mail
Atrial Fibrillation Market | Global Market Analysis Report2036 - Fact.MR
Will AtriCure Inc. stock benefit from automation2025 Sector Review & Reliable Intraday Trade Plans - DonanımHaber
Will AtriCure Inc. stock continue upward momentum2025 Earnings Surprises & Low Risk Profit Maximizing Plans - DonanımHaber
Understanding the Setup: (ATRC) and Scalable Risk - Stock Traders Daily
How supply chain issues affect AtriCure Inc. stockJuly 2025 Spike Watch & Safe Capital Preservation Plans - Улправда
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference - BioSpace
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way? - 富途牛牛
AtriCure Earnings Notes - Trefis
JP Morgan Raises AtriCure (ATRC) Price Target to $48 | ATRC Stoc - GuruFocus
ATRC FinancialsIncome Statement - Quiver Quantitative
JPMorgan Chase & Co. Boosts AtriCure (NASDAQ:ATRC) Price Target to $48.00 - MarketBeat
AtriCure, Inc. $ATRC Shares Acquired by Squarepoint Ops LLC - MarketBeat
AtriCure (ATRC) Is Up 6.3% After First Dual-Energy PFA–RFA Human Procedures Success - Sahm
AtriCure (ATRC) Is Up 6.3% After Dual Energy PFA–RFA First-in-Human SuccessHas The Bull Case Changed? - Yahoo Finance
Loss Report: What valuation multiples suggest for AtriCure Inc stockJuly 2025 Outlook & Fast Entry Momentum Alerts - moha.gov.vn
AtriCure treats first patients with dual PFA/RF system - MedTech Dive
ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform - Finviz
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year? - MSN
CEO Carrel Gifts 4,000 Of AtriCure Inc [ATRC] - TradingView — Track All Markets
AtriCure’s Cryoanalgesia Study: A Potential Game-Changer in Post-Operative Pain Management - MSN
AtriCure reports first patients treated with dual-energy PFA, RF platform - MassDevice
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform - 01net
AtriCure, Inc. Announces the First Patients Treated with Novel Dual Energy Platform - marketscreener.com
AtriCure Reports 1st Treatments with Dual Energy RF, PFA System - Medical Product Outsourcing
AtriCure Says First Patients Treated With Dual-Energy Platform - marketscreener.com
AtriCure (ATRC) Introduces Cutting-Edge Dual Energy Platform in Initial Treatments - GuruFocus
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):